Home > Publications database > Letter to the editor re: CDX2 expression as a predictive and prognostic biomarker of 5-fluorouracil response in cancer of unknown primary. > print

001     304605
005     20250919115037.0
024 7 _ |a 10.1016/j.esmoop.2025.105812
|2 doi
024 7 _ |a pmid:40961643
|2 pmid
037 _ _ |a DKFZ-2025-01924
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Krämer, Alwin
|0 P:(DE-He78)493c5fbf69f1b20df6f048712f3ad4a0
|b 0
|e Last author
|u dkfz
245 _ _ |a Letter to the editor re: CDX2 expression as a predictive and prognostic biomarker of 5-fluorouracil response in cancer of unknown primary.
260 _ _ |a [London]
|c 2025
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1758201396_22717
|2 PUB:(DE-HGF)
|x Letter
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #LA:A360#
536 _ _ |a 311 - Zellbiologie und Tumorbiologie (POF4-311)
|0 G:(DE-HGF)POF4-311
|c POF4-311
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
773 _ _ |a 10.1016/j.esmoop.2025.105812
|g Vol. 10, no. 10, p. 105812 -
|0 PERI:(DE-600)2844985-X
|n 10
|p 105812
|t ESMO open
|v 10
|y 2025
|x 2059-7029
909 C O |o oai:inrepo02.dkfz.de:304605
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)493c5fbf69f1b20df6f048712f3ad4a0
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-311
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Zellbiologie und Tumorbiologie
|x 0
914 1 _ |y 2025
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ESMO OPEN : 2022
|d 2024-12-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-04-12T14:49:18Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-04-12T14:49:18Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2023-04-12T14:49:18Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-30
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-30
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b ESMO OPEN : 2022
|d 2024-12-30
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-30
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-30
920 2 _ |0 I:(DE-He78)A360-20160331
|k A360
|l KKE Mol. Hämatologie/Onkologie
|x 0
920 1 _ |0 I:(DE-He78)A360-20160331
|k A360
|l KKE Mol. Hämatologie/Onkologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)A360-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21